Sarfaraz K. Niazi, PhD, explained why Indian manufacturers aren’t bringing biosimilars to the United States and how FDA policies and procedures discourage global companies from pursuing US market entry.
So far, the maximum price discount for biosimilars are Amgen's Avsola (infliximab-axxq), 57% lower than Remicade (reference infliximab), and Amjevita (adalimumab-atto), a 55% discount to Humira (reference adalimumab). Next in line is the biosimilar Amneal Pharmaceuticals and Kashiv Biosciences developed, Releuko (filgrastim-ayow), which offers a 50% discount to Amgen's Neupogen.
While some have predicted that an 80% to 90% discount from Humira biosimilars is prominent, the consensus is that the future competition within the biosimilar markets will be less than expected, as reported by Barclays bank.
Therefore, high discounts will likely not materialize for years, based on the average 26% discount for products launched before 2020. The reason for this shift in predictions is based on prospects for the entry of biosimilars from India and China, the 2 sources capable of disrupting the market. Here is my analysis of why these sources of biosimilars need to show success and how a shift can be made.
A significant market disrupter, the entry of Indian biosimilar companies,—except for Biocon, which had many issues—has not yet become a reality and is not expected soon. One reason why Indian companies are not likely to enter the US biosimilars market, despite having done so in the generics market, has to do with the biosimilar regulations in India, which leaves a poor impression of the quality of Indian biosimilars and requires a complete rework if Indian companies plan to introduce the 100 plus biosimilars now available in India to the US market. Indian biosimilar companies are already selling these products and generating very small revenue, which reduces the incentive to invest in the US market.
For example, the FDA and the European Medicines Agency no longer require "animal toxicology" data because animal species do not have receptors to demonstrate biological drugs' pharmacology and toxicology.
However, guidelines from the Indian Central Drugs Standard Control Organisation(CDSCO) state "the applicant should provide the scientific justification for the choice of animal model(s) based on the data available in scientific literature. However, if the relevant animal species is unavailable and has been appropriately justified, toxicity studies must be undertaken in two species, i.e., one rodent and another non-rodent species. The dose should be calculated based on the therapeutic dose of the reference biologic. A pilot dose-response study should be conducted before initiating the toxicity studies."
The Indian guidelines further state: "Information to establish comparative safety and efficacy in relevant patient population is mandatory for all similar biologics…. Also, in cases where phase 3 data on the Indian population is necessary, a single-arm study in at least 100 evaluable subjects may be carried out in the most sensitive indication ‘to address any residual uncertainty.’”
There is no scientific rationale for these suggestions. The size of a clinical trial is calculated based on the alpha value, the beta value, and the prior variability between subjects. Any meaningful comparison may require thousands of subjects. The studies proposed by the CDSCO can never fail and serve only as a token checklist.
These, and many other inconsistencies in the Indian guidance, have eroded the confidence in the biosimilars approved in India. To plan entry into the United States, the Indian marketers will have to start it all over again, including compliance assurance, a financial challenge that keeps them away; why risk when their products are already selling, albeit for pennies is the thought process.
Moreover, some who have tried, such as Intas Pharmaceuticals, have been waiting for almost 10 years to hear back from the FDA on its biosimilar filings. Recently, the FDA flagged Intas with an FDA warning letter (Form 483) for significant violations within the company’s manufacturing plant, and it is unlikely that any biosimilar product will come from Intas soon.
Acknowledging their inability, some Indian companies, such as Lupin Limited, are abandoning the US market after receiving multiple warning letters from the FDA.
It is also unlikely that Chinese companies will enter the biosimilar competition in the United States for additional reasons than those cited for the Indian products.[1] In recent years, China’s biosimilar drug industry has developed rapidly. By the end of 2019, China had the highest number of biosimilar drugs in development (n = 391 biosimilars).
The laws and regulations for biosimilar drugs in China, particularly a complete registration management system and supporting policies for supervising biosimilar drugs, have not been established yet. This has brought much confusion in the biopharmaceutical industry in China. However, China can introduce regulations that will help the sector develop globally acceptable products by not repeating the mistakes of creating guidelines for generic chemical products.[2]
While India and China are the major expected sources, the FDA has also sent a complete response letter for other biosimilar prospects, like Alvotech’s adalimumab biosimilar (AVT02), creating delays in market entry and discouragement for global developers.
Previously, I predicted that the big pharma engaging with biosimilars would leave the market as prices fall below 50% of the innovator product. However, the bold move by Amgen, with the highest discount for its biosimilar products, may change my perspective as long as the cost of development remains between $200 million and $300 million.
This prediction is only delayed; once the regulatory requirements become harmonized and more rational in the United States, such as removing the requirement for phase 3 studies, 7 companies in India and China may reconsider entry. But, that will most likely take at least a decade.
For now, the US model will hover around a 50% discount, and big pharma remains in the lead to supply biosimilars. This will hurt the possibility of over 100 biosimilars from entering the US market, which will not be of least interest to big pharma, because smaller market allow them to leave their higher prices in place.
References
[1] Yang J, Zhao X, Li J, et al. Creating China's biosimilar drugs regulatory system: A calculated approach. Front Pharmacol. 2022;13:815074. doi:10.3389/fphar.2022.815074
[2] Huang B, Barber SL, Xu M, Cheng S. Make up a missed lesson: New policy to ensure the interchangeability of generic drugs in China. Pharma Res. 2017;5(3): e00318. doi:10.1002/prp2.318
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.